About Regulation of nuclear pre-mRNA domain-containing protein 1A
Regulation of nuclear pre-mRNA domain-containing protein 1A (RPRD1A) is a protein
from Homo sapiens identified by UniProt accession
Q96P16, 312 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Regulation of nuclear pre-mRNA domain-containing protein 1A |
|---|
| UniProt accession | Q96P16 |
|---|
| Gene | RPRD1A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 312 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (17)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin · score 0.27
- mean corpuscular hemoglobin concentration · score 0.27
- mean corpuscular volume · score 0.24
- hepatocellular carcinoma · score 0.07
- neoplasm · score 0.06
- gonorrhea · score 0.05
- protein measurement · score 0.04
- eosinophilic esophagitis · score 0.02
- cancer · score 0.01
- acute myeloid leukemia · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96P16-F1 | alphafold | PREDICTED | 83.34 | — |
Amino-acid sequence (312 residues)
MSAFSEAALE KKLSELSNSQ QSVQTLSLWL IHHRKHSRPI VTVWERELRK AKPNRKLTFL YLANDVIQNS KRKGPEFTKD FAPVIVEAFK HVSSETDESC KKHLGRVLSI WEERSVYEND VLEQLKQALY GDKKPRKRTY EQIKVDENEN CSSLGSPSEP PQTLDLVRAL QDLENAASGD AAVHQRIASL PVEVQEVSLL DKITDKESGE RLSKMVEDAC MLLADYNGRL AAEIDDRKQL TRMLADFLRC QKEALAEKEH KLEEYKRKLA RVSLVRKELR SRIQSLPDLS RLPNVTGSHM HLPFAGDIYS ED
Explore Regulation of nuclear pre-mRNA domain-containing protein 1A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets